PLX
Price
$1.72
Change
-$1.17 (-40.48%)
Updated
May 9 closing price
Capitalization
229.8M
100 days until earnings call
XCUR
Price
$11.44
Change
+$0.06 (+0.53%)
Updated
May 9 closing price
Capitalization
71.9M
Ad is loading...

PLX vs XCUR

Header iconPLX vs XCUR Comparison
Open Charts PLX vs XCURBanner chart's image
Protalix BioTherapeutics
Price$1.72
Change-$1.17 (-40.48%)
Volume$5.95M
Capitalization229.8M
Exicure
Price$11.44
Change+$0.06 (+0.53%)
Volume$5.99K
Capitalization71.9M
PLX vs XCUR Comparison Chart
Loading...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PLX vs. XCUR commentary
May 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLX is a Buy and XCUR is a Buy.

Ad is loading...
COMPARISON
Comparison
May 10, 2025
Stock price -- (PLX: $1.72 vs. XCUR: $11.44)
Brand notoriety: PLX and XCUR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PLX: 680% vs. XCUR: 19%
Market capitalization -- PLX: $229.8M vs. XCUR: $71.9M
PLX [@Biotechnology] is valued at $229.8M. XCUR’s [@Biotechnology] market capitalization is $71.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLX’s FA Score shows that 1 FA rating(s) are green whileXCUR’s FA Score has 0 green FA rating(s).

  • PLX’s FA Score: 1 green, 4 red.
  • XCUR’s FA Score: 0 green, 5 red.
According to our system of comparison, PLX is a better buy in the long-term than XCUR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLX’s TA Score shows that 6 TA indicator(s) are bullish while XCUR’s TA Score has 6 bullish TA indicator(s).

  • PLX’s TA Score: 6 bullish, 4 bearish.
  • XCUR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both PLX and XCUR are a good buy in the short-term.

Price Growth

PLX (@Biotechnology) experienced а -42.67% price change this week, while XCUR (@Biotechnology) price change was +6.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

PLX is expected to report earnings on Aug 18, 2025.

XCUR is expected to report earnings on Aug 13, 2024.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PLX($230M) has a higher market cap than XCUR($71.9M). PLX has higher P/E ratio than XCUR: PLX (68.25) vs XCUR (0.19). PLX YTD gains are higher at: -8.511 vs. XCUR (-16.313). XCUR has higher annual earnings (EBITDA): -3.17M vs. PLX (-6.48M). PLX has more cash in the bank: 27.4M vs. XCUR (343K). PLX has less debt than XCUR: PLX (5.68M) vs XCUR (6.13M). PLX has higher revenues than XCUR: PLX (45.7M) vs XCUR (500K).
PLXXCURPLX / XCUR
Capitalization230M71.9M320%
EBITDA-6.48M-3.17M204%
Gain YTD-8.511-16.31352%
P/E Ratio68.250.1936,529%
Revenue45.7M500K9,140%
Total Cash27.4M343K7,988%
Total Debt5.68M6.13M93%
FUNDAMENTALS RATINGS
PLX vs XCUR: Fundamental Ratings
PLX
XCUR
OUTLOOK RATING
1..100
850
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9195
PRICE GROWTH RATING
1..100
3534
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XCUR's Valuation (70) in the null industry is in the same range as PLX (80) in the Servicestothe Health Industry industry. This means that XCUR’s stock grew similarly to PLX’s over the last 12 months.

XCUR's Profit vs Risk Rating (100) in the null industry is in the same range as PLX (100) in the Servicestothe Health Industry industry. This means that XCUR’s stock grew similarly to PLX’s over the last 12 months.

PLX's SMR Rating (91) in the Servicestothe Health Industry industry is in the same range as XCUR (95) in the null industry. This means that PLX’s stock grew similarly to XCUR’s over the last 12 months.

XCUR's Price Growth Rating (34) in the null industry is in the same range as PLX (35) in the Servicestothe Health Industry industry. This means that XCUR’s stock grew similarly to PLX’s over the last 12 months.

PLX's P/E Growth Rating (2) in the Servicestothe Health Industry industry is significantly better than the same rating for XCUR (100) in the null industry. This means that PLX’s stock grew significantly faster than XCUR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PLXXCUR
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
80%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRWIX37.89N/A
N/A
AMG Boston Common Global Impact I
FIIAX21.09N/A
N/A
Fidelity Advisor Mid Cap II A
MELIX15.34N/A
N/A
Morgan Stanley Inst EMkts Ldrs I
MSDUX12.61N/A
N/A
Morgan Stanley Emerging Mkt ex China I
WSTYX59.47-0.26
-0.44%
Macquarie Science and Technology Y

PLX and

Correlation & Price change

A.I.dvisor tells us that PLX and STOK have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PLX and STOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
-40.48%
STOK - PLX
31%
Poorly correlated
+3.43%
ZNTL - PLX
31%
Poorly correlated
-2.38%
CPRX - PLX
31%
Poorly correlated
+2.68%
SNDX - PLX
31%
Poorly correlated
-2.82%
LXRX - PLX
31%
Poorly correlated
+1.73%
More

XCUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XCUR has been loosely correlated with XFOR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XCUR jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
+0.53%
XFOR - XCUR
34%
Loosely correlated
+2.43%
ALNY - XCUR
26%
Poorly correlated
-2.79%
NNVC - XCUR
25%
Poorly correlated
-6.38%
PLX - XCUR
25%
Poorly correlated
-40.48%
KRYS - XCUR
24%
Poorly correlated
-3.64%
More